JP2018537535A5 - - Google Patents

Download PDF

Info

Publication number
JP2018537535A5
JP2018537535A5 JP2018549403A JP2018549403A JP2018537535A5 JP 2018537535 A5 JP2018537535 A5 JP 2018537535A5 JP 2018549403 A JP2018549403 A JP 2018549403A JP 2018549403 A JP2018549403 A JP 2018549403A JP 2018537535 A5 JP2018537535 A5 JP 2018537535A5
Authority
JP
Japan
Prior art keywords
compound according
ring
optionally substituted
fluorine
aliphatic group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018549403A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018537535A (ja
JP6810156B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/065865 external-priority patent/WO2017100601A1/en
Publication of JP2018537535A publication Critical patent/JP2018537535A/ja
Publication of JP2018537535A5 publication Critical patent/JP2018537535A5/ja
Application granted granted Critical
Publication of JP6810156B2 publication Critical patent/JP6810156B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018549403A 2015-12-09 2016-12-09 Pad4のアザベンゾイミダゾール阻害剤 Active JP6810156B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562264919P 2015-12-09 2015-12-09
US62/264,919 2015-12-09
PCT/US2016/065865 WO2017100601A1 (en) 2015-12-09 2016-12-09 Aza-benzimidazole inhibitors of pad4

Publications (3)

Publication Number Publication Date
JP2018537535A JP2018537535A (ja) 2018-12-20
JP2018537535A5 true JP2018537535A5 (enExample) 2020-01-23
JP6810156B2 JP6810156B2 (ja) 2021-01-06

Family

ID=59013635

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018549403A Active JP6810156B2 (ja) 2015-12-09 2016-12-09 Pad4のアザベンゾイミダゾール阻害剤

Country Status (17)

Country Link
US (1) US9765093B2 (enExample)
EP (1) EP3386505B1 (enExample)
JP (1) JP6810156B2 (enExample)
KR (1) KR102683681B1 (enExample)
CN (1) CN108601770B (enExample)
AR (1) AR107030A1 (enExample)
AU (1) AU2016366405A1 (enExample)
BR (1) BR112018011633A2 (enExample)
CA (1) CA3007954A1 (enExample)
EA (1) EA201891347A1 (enExample)
ES (1) ES2830353T3 (enExample)
IL (1) IL259796A (enExample)
MX (1) MX2018006700A (enExample)
SG (1) SG11201804671SA (enExample)
TW (1) TW201726689A (enExample)
UY (1) UY37017A (enExample)
WO (1) WO2017100601A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109071497B (zh) 2016-02-23 2021-10-22 帕德罗科治疗公司 Pad4杂芳基抑制剂
US10703741B2 (en) 2016-07-27 2020-07-07 Padlock Therapeutics, Inc. Covalent inhibitors of PAD4
ES2924522T3 (es) 2016-09-12 2022-10-07 Padlock Therapeutics Inc Inhibidores heteroarilo de PAD4
US11981680B2 (en) 2018-08-08 2024-05-14 Bristol-Myers Squibb Company Substituted thienopyrroles as PAD4 inhibitors
SG11202101176YA (en) * 2018-08-08 2021-03-30 Bristol Myers Squibb Co Substituted benzimidazoles as pad4 inhibitors
US20220348562A1 (en) * 2018-08-08 2022-11-03 Bristol-Myers Squibb Company Benzimidazole inhibitors of pad enzymes
CN112805067A (zh) 2018-08-08 2021-05-14 百时美施贵宝公司 Pad酶的吲哚及氮杂吲哚抑制剂
JP7711073B2 (ja) * 2020-02-06 2025-07-22 ブリストル-マイヤーズ スクイブ カンパニー 免疫抑制剤として有用な大環状pad4阻害剤
TW202140477A (zh) * 2020-02-12 2021-11-01 美商必治妥美雅史谷比公司 雜環pad4抑制劑
BR112022021963A2 (pt) 2020-04-30 2022-12-13 Gilead Sciences Inc Inibidores macrocíclicos de peptidilarginina desiminases
TW202241884A (zh) 2020-12-22 2022-11-01 美商基利科學股份有限公司 肽基精胺酸去亞胺酶之抑制劑
US12240862B2 (en) 2020-12-22 2025-03-04 Gilead Sciences, Inc. Inhibitors of peptidylarginine deiminases
WO2025024265A1 (en) 2023-07-21 2025-01-30 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad4 modulators
WO2025199042A1 (en) * 2024-03-18 2025-09-25 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Methods for treating severe tuberculosis
WO2026020127A2 (en) 2024-07-19 2026-01-22 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad2 modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) * 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
FR2826653B1 (fr) 2001-06-29 2005-10-14 Servier Lab Nouveaux derives de pyrido-pyrido-pyrrolo[3,2-g]pyrrolo [3,4-e]-indole et pyrido-pyrrolo[2,3-a]pyrrolo[3,4-c] carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MXPA04003954A (es) * 2001-10-26 2004-11-29 Aventis Pharma Inc Bencimidazoles.
FR2862971B1 (fr) * 2003-11-28 2006-03-24 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
WO2010051245A1 (en) * 2008-11-03 2010-05-06 Merck Sharp & Dohme Corp. Benzimidazole and aza-benzimidazole carboxamides
CA2879341C (en) * 2012-07-26 2019-06-11 Glaxo Group Limited 2- (azaindol-2-yl) benzimidazoles as pad4 inhibitors

Similar Documents

Publication Publication Date Title
JP2018537535A5 (enExample)
JP2018021051A5 (enExample)
JP2019537570A5 (enExample)
JP2013542261A5 (enExample)
JP2016534063A5 (enExample)
JP2019509276A5 (enExample)
JP2012513416A5 (enExample)
JP2019516739A5 (enExample)
JP2014508752A5 (enExample)
JP2012524056A5 (enExample)
JP2016518437A5 (enExample)
JP2014511892A5 (enExample)
JP2017528503A5 (enExample)
JP2017504635A5 (enExample)
JP2016528301A5 (enExample)
JP2014506907A5 (enExample)
JP2016527217A5 (enExample)
JP2016503797A5 (enExample)
JP2017517538A5 (enExample)
JP2015500223A5 (enExample)
JP2020507589A5 (enExample)
JP2017501236A5 (enExample)
JP2015508092A5 (enExample)
JP2019535723A5 (enExample)
JP2019505529A5 (enExample)